Developer docs
API playgroundTry for free, no card

Search company profiles

iBio

Full company profile

uuid0000o21

Namestring
iBio
Legal namestring
iBio, Inc.
Websiteurl
ibioinc.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

iBio, Inc. is a clinical-stage biotechnology company that discovers and develops precision antibody therapeutics using a proprietary AI-driven discovery platform. The company, headquartered in San Diego, California and listed on NASDAQ (IBIO), was originally a contract development and manufacturing organization (CDMO) before pivoting to focus on AI-enabled antibody discovery for obesity, cardiometabolic disease, and oncology.

The company's core technology stack integrates three proprietary components: (1) Epitope Steering, a patented AI engine that engineers and directs antibody binding to defined functional regions on target proteins; (2) StableHu, a generative AI tool trained on over one billion human antibody sequences that predicts optimized CDR variants for humanization, stability, and developability; and (3) mammalian display-based multidimensional screening for simultaneous optimization of affinity, specificity, and half-life. Additional platform assets include EngageTx (CD3 T-cell engager panel for bispecific oncology antibodies) and ShieldTx (conditionally activated antibody masking for improved safety). The platform is reported to enable progression from concept to development-ready antibody in approximately seven months. Lead clinical asset IBIO-600, an anti-myostatin monoclonal antibody for obesity and cardiometabolic disease, entered Phase 1 dosing in June 2026 following Australian TGA approval. Preclinical lead IBIO-610 (Activin E antibody) targets fat-selective weight loss with predicted twice-yearly human dosing. Additional programs include a myostatin x activin A bispecific, an anti-CD25 antibody (IBIO-101), TROP-2 x CD3 and MUC16 bispecifics for oncology, and an amylin receptor agonist program.

iBio has no current product revenue and is funded primarily through equity financings. The company closed approximately $50 million in an August 2025 public offering and approximately $26 million in a January 2026 private placement led by Frazier Life Sciences, with cash of approximately $74.8 million as of Q3 FY2026 extending runway into calendar 2028. Revenue economics are expected to derive from future product sales, out-licensing of platform technologies and pipeline assets (e.g., AstralBio collaboration), or partnership deals with larger pharmaceutical companies. The primary customer segment is patients with obesity and cardiometabolic disease underserved by current GLP-1 therapies, with the company also pursuing strategic collaborations with pharmaceutical partners in immunology, infectious disease, and oncology.

Short descriptiontext

iBio is a clinical-stage biotech developing AI-designed antibody therapeutics for obesity, cardiometabolic disease, and oncology, with lead asset IBIO-600 in Phase 1 trials and IBIO-610 in late preclinical development. The company is pre-revenue, publicly listed on NASDAQ, and funded through equity financings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNewark, United States
HQ citystring
Newark
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI antibody discovery, antibody therapeutics, obesity drug development, cardiometabolic biologics, biopharmaceutical pipeline
Industry2 codes
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biopharmaceutical Drug Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Biopharmaceutical Development & Commercialization
TypeOne Time License
Description

iBio is a preclinical-stage biotech company with no current product revenue. The company is developing a pipeline of antibody therapeutics (IBIO-600, IBIO-610, bispecific programs) targeting obesity and cardiometabolic diseases. Revenue would be generated through eventual product sales upon regulatory approval or through licensing/partnership deals with larger pharmaceutical companies.

ir.ibioinc.com
2Strategic Licensing & Partnership Deals
TypeLicensing Royalties
Description

The company generates value and potential revenue through licensing its technology platform and pipeline assets to pharmaceutical partners. The company has formed collaborations with AstralBio for multi-target obesity programs, with options to license targets. iBio also out-licenses platform technologies (AI epitope steering, EngageTx, ShieldTx) in therapeutic areas outside its core focus.

ir.ibioinc.com
3Financing / Capital Markets
TypeSubscription Recurring
Description

As a preclinical biotech with no product revenue, the company funds operations through equity financings including private placements, public offerings, and warrant exercises. Recent financings include a $50M public offering (August 2025), $26M private placement (January 2026), and $15M private placement (March 2024).

ir.ibioinc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

iBio is a clinical-stage biotechnology company that discovers and develops precision antibody therapeutics for obesity and cardiometabolic diseases using an integrated AI Drug Discovery Platform. The platform combines Epitope Steering AI, StableHu generative AI antibody optimization, and mammalian display screening to engineer antibodies against hard-to-drug targets. Lead programs include IBIO-600 (anti-myostatin antibody in Phase 1) and IBIO-610 (Activin E antibody in late preclinical), with additional oncology bispecific programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • IBIO-610 demonstrated 8.9% body weight reduction vs baseline and placebo in DIO mouse model with 26% fat mass reduction and no measurable lean mass loss
+4 more records
Product overview1 text field

iBio is a preclinical-stage biotech company developing a pipeline of next-generation antibody therapeutics for obesity, cardiometabolic diseases, and cancer using an integrated AI Drug Discovery Platform. The platform combines three core technology components: Epitope Steering (AI-powered epitope targeting), StableHu (generative AI antibody optimization), and mammalian display-based screening. The company's lead clinical candidate IBIO-600 (anti-myostatin antibody for muscle preservation in obesity) entered Phase 1 trials in 2026. IBIO-610 (Activin E antibody for fat-selective weight loss) is in late preclinical stage with clinical trials expected in 2027. Additional programs include a myostatin x activin A bispecific antibody, bispecific T-cell engagers (EngageTx) for cancer, and masked antibody technology (ShieldTx) for improved safety. Partnered programs include Amylin receptor agonists and multiple obesity targets via AstralBio collaboration.

Product and service13 records
1AI Drug Discovery Platform
CategoryDrug discovery platform
Description

Integrated AI-powered platform combining epitope engineering, StableHu antibody optimization, and mammalian display screening for discovering and developing precision antibodies against hard-to-drug targets. Enables progression from concept to development-ready antibody in approximately seven months. Sold/licensed to pharmaceutical partners.

2Epitope Steering Technology
CategoryAI-driven antibody technology
Description

Patented AI engine that directs antibody binding to precisely defined functional regions (epitopes) on target proteins. Enables creation of antibodies with complex modes of action against previously undruggable targets including GPCRs and TGF-beta family proteins. Out-licensed to pharmaceutical partners in therapeutic areas outside iBio's core focus.

3StableHu AI Antibody Optimization
CategoryAI-driven antibody technology
Description

Generative AI tool that predicts optimized human antibody CDR sequences and optimizes antibodies for expression, stability, and manufacturability. Trained on over 1 billion human antibody sequences. Provides focused library diversity for mammalian display optimization.

4EngageTx CD3 T-Cell Engager Panel
CategoryBispecific antibody technology
Description

Next-generation CD3 antibody panel with wide range of potencies, NHP cross-reactivity, enhanced humanness, and strong tumor-killing activity with reduced cytokine release. Used for developing bispecific T-cell engagers for cancer treatment. Out-licensed to pharmaceutical partners.

5ShieldTx Antibody Masking Technology
CategoryAntibody engineering technology
Description

Antibody masking technology that creates conditionally activated antibodies, keeping them inactive until reaching diseased tissue where masks are cleaved off by tissue-specific enzymes. Broadens therapeutic window and improves safety profiles. Out-licensed to pharmaceutical partners.

6IBIO-600
CategoryTherapeutic antibody candidate
Description

Long-acting anti-myostatin monoclonal antibody designed to preserve lean mass and improve body composition in obesity patients. Targets myostatin and GDF11, engineered for infrequent dosing (2-4 times per year). Entered Phase 1 clinical trial in June 2026 for adults with overweight/obesity.

7IBIO-610
CategoryTherapeutic antibody candidate
Description

Activin E antibody for fat-selective weight loss and weight maintenance. Demonstrated 26% reduction in fat mass with no lean mass loss in preclinical studies. Extended half-life of up to 100 days in non-human primates, supporting twice-yearly dosing. Development candidate with clinical trials expected in 2027.

8Myostatin x Activin A Bispecific Antibody
CategoryTherapeutic antibody candidate
Description

Bispecific antibody simultaneously targeting myostatin and Activin A to maximize lean mass preservation. In late discovery stage with multiple parameters being optimized. Showed stronger differentiation of progenitor cells into mature muscle cells compared to single-target antibodies.

9IBIO-101
CategoryTherapeutic antibody candidate
Description

Second-generation anti-CD25 monoclonal antibody for immuno-oncology, designed to deplete immunosuppressive regulatory T cells while preserving interleukin-2 signaling in effector T cells. Addresses key limitations of first-generation anti-CD25 therapies.

10TROP-2 x CD3 Bispecific Antibody
CategoryTherapeutic antibody candidate
Description

Bispecific antibody developed with EngageTx platform to selectively kill TROP-2-expressing tumors while minimizing cytokine release. TROP-2 is highly expressed in breast, lung, colorectal, and pancreatic cancers. Demonstrated 36% tumor size reduction in preclinical studies.

11MUC16 Antibody Program
CategoryTherapeutic antibody candidate
Description

Antibody targeting non-shed, non-glycosylated region of MUC16 to avoid tumor immune evasion mechanisms. MUC16 is overexpressed in multiple solid tumors including over 80% of ovarian cancers. Lead molecules selectively bind engineered epitope and tumor cells.

12CCR8 Antibody Program
CategoryTherapeutic antibody candidate
Description

Anti-CCR8 antibodies with high specificity for depleting immunosuppressive tumor-associated regulatory T cells while sparing CCR4-expressing cells. Demonstrated 22% tumor size reduction in colon cancer mouse model.

13Amylin Receptor Agonist Program
CategoryTherapeutic antibody candidate
Description

Antibody-based amylin receptor agonist developed in collaboration with AstralBio for long-term weight regulation. Early DACRA-like agonist antibody showed approximately 60% reduction in acute food intake in preclinical studies.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-27
Description

Discovery, Option and License Agreement entered March 27, 2024 for multi-target collaboration focused on genetically validated pathways in obesity and cardiometabolic disease. iBio granted exclusive license to its AI-powered technology to identify and engineer four targets, with options to license three obesity/cardiometabolic targets from AstralBio. Collaboration expanded in April 2025 to add a fifth target. iBio exercised options for exclusive licenses to IBIO-600 (myostatin, December 2024) and IBIO-610 (Activin E, January 2025 / April 2025), securing worldwide development and commercialization rights for both assets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Dominant incumbent in obesity with Mounjaro/Zepbound (tirzepatide) and next-gen candidates (retatrutide). Broad incumbent defining the competitive context for iBio's muscle-preservation obesity programs and the most likely strategic acquirer/licensing partner.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics for metabolic diseases including obesity, with a focus on muscle biology and aging-related pathways. Comparable emerging obesity/cardiometabolic player with overlapping target rationale (myostatin/Activin biology).

TypeDirect peer
Description

AI-driven generative biology company developing novel protein therapeutics, including antibodies. Operates a similar AI-first antibody/protein engineering platform paradigm with comparable therapeutic ambitions across cardiometabolic and oncology indications.

TypeDirect peer
Description

Public antibody discovery platform company combining AI/machine learning with single-cell screening for therapeutic antibody discovery. Directly comparable to iBio's StableHu + mammalian display approach and serves similar biopharma partners.

TypeDirect peer
Description

Clinical-stage AI-powered antibody discovery and engineering company using computational biology platforms to design antibodies with conditional activation (POWER platforms). Direct peer to iBio's ShieldTx masking and epitope steering approaches.

TypeEmerging player
Description

Clinical-stage biotech developing bispecific antibodies for oncology, including T-cell engagers. Comparable to iBio's EngageTx CD3 platform and bispecific oncology pipeline (TROP-2 x CD3).

TypeEmerging player
Description

Clinical-stage company developing oral small molecules for cardiometabolic diseases including obesity and GLP-1 receptor agonists. Targets overlapping obesity patient population with a complementary (oral small molecule) modality.

TypeEmerging player
Description

Public endocrine disease biotech with peptide platform advancing programs in acromegaly and obesity. Comparable clinical-stage obesity/cardiometabolic player, though differentiated by small molecule/peptide modality versus iBio's biologics.

TypeDirect peer
Description

AI/ML-guided antibody design platform combining machine learning with wet-lab validation, including mammalian display. Direct peer to iBio's StableHu + mammalian display technology stack targeting hard-to-drug proteins.

TypeBroad incumbent
Description

Public computational drug discovery platform serving pharma clients with physics-based and AI molecular design across small molecules and biologics. Broader incumbent in computational/AI drug discovery with established software-plus-services business model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iBio

Biopharmaceutical Drug Developmentibioinc.com

iBio is a clinical-stage biotech developing AI-designed antibody therapeutics for obesity, cardiometabolic disease, and oncology, with lead asset IBIO-600 in Phase 1 trials and IBIO-610 in late preclinical development. The company is pre-revenue, publicly listed on NASDAQ, and funded through equity financings.

What iBio does

iBio, Inc. is a clinical-stage biotechnology company that discovers and develops precision antibody therapeutics using a proprietary AI-driven discovery platform. The company, headquartered in San Diego, California and listed on NASDAQ (IBIO), was originally a contract development and manufacturing organization (CDMO) before pivoting to focus on AI-enabled antibody discovery for obesity, cardiometabolic disease, and oncology.

The company's core technology stack integrates three proprietary components: (1) Epitope Steering, a patented AI engine that engineers and directs antibody binding to defined functional regions on target proteins; (2) StableHu, a generative AI tool trained on over one billion human antibody sequences that predicts optimized CDR variants for humanization, stability, and developability; and (3) mammalian display-based multidimensional screening for simultaneous optimization of affinity, specificity, and half-life. Additional platform assets include EngageTx (CD3 T-cell engager panel for bispecific oncology antibodies) and ShieldTx (conditionally activated antibody masking for improved safety). The platform is reported to enable progression from concept to development-ready antibody in approximately seven months. Lead clinical asset IBIO-600, an anti-myostatin monoclonal antibody for obesity and cardiometabolic disease, entered Phase 1 dosing in June 2026 following Australian TGA approval. Preclinical lead IBIO-610 (Activin E antibody) targets fat-selective weight loss with predicted twice-yearly human dosing. Additional programs include a myostatin x activin A bispecific, an anti-CD25 antibody (IBIO-101), TROP-2 x CD3 and MUC16 bispecifics for oncology, and an amylin receptor agonist program.

iBio has no current product revenue and is funded primarily through equity financings. The company closed approximately $50 million in an August 2025 public offering and approximately $26 million in a January 2026 private placement led by Frazier Life Sciences, with cash of approximately $74.8 million as of Q3 FY2026 extending runway into calendar 2028. Revenue economics are expected to derive from future product sales, out-licensing of platform technologies and pipeline assets (e.g., AstralBio collaboration), or partnership deals with larger pharmaceutical companies. The primary customer segment is patients with obesity and cardiometabolic disease underserved by current GLP-1 therapies, with the company also pursuing strategic collaborations with pharmaceutical partners in immunology, infectious disease, and oncology.

iBio firmographics

Firmographics
Name
iBio
Legal name
iBio, Inc.
Website
https://ibioinc.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
51–100 employees
Short description
iBio is a clinical-stage biotech developing AI-designed antibody therapeutics for obesity, cardiometabolic disease, and oncology, with lead asset IBIO-600 in Phase 1 trials and IBIO-610 in late preclinical development. The company is pre-revenue, publicly listed on NASDAQ, and funded through equity financings.
Ownership category
akta.pro rank

iBio industry classification

Industry
Product category
Biopharmaceutical Drug Development
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI antibody discovery
  • Antibody therapeutics
  • Obesity drug development
  • Cardiometabolic biologics
  • Biopharmaceutical pipeline

Where iBio is headquartered

Location

Headquarters

HQ city
Newark
HQ country
United States
HQ region
North America

Offices3 records

Markets served

iBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biopharmaceutical Development & Commercialization: iBio is a preclinical-stage biotech company with no current product revenue. The company is developing a pipeline of antibody therapeutics (IBIO-600, IBIO-610, bispecific programs) targeting obesity and cardiometabolic diseases. Revenue would be generated through eventual product sales upon regulatory approval or through licensing/partnership deals with larger pharmaceutical companies.
  2. Strategic Licensing & Partnership Deals: The company generates value and potential revenue through licensing its technology platform and pipeline assets to pharmaceutical partners. The company has formed collaborations with AstralBio for multi-target obesity programs, with options to license targets. iBio also out-licenses platform technologies (AI epitope steering, EngageTx, ShieldTx) in therapeutic areas outside its core focus.
  3. Financing / Capital Markets: As a preclinical biotech with no product revenue, the company funds operations through equity financings including private placements, public offerings, and warrant exercises. Recent financings include a $50M public offering (August 2025), $26M private placement (January 2026), and $15M private placement (March 2024).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

iBio product offering

Product offering

Core offering

iBio is a clinical-stage biotechnology company that discovers and develops precision antibody therapeutics for obesity and cardiometabolic diseases using an integrated AI Drug Discovery Platform. The platform combines Epitope Steering AI, StableHu generative AI antibody optimization, and mammalian display screening to engineer antibodies against hard-to-drug targets. Lead programs include IBIO-600 (anti-myostatin antibody in Phase 1) and IBIO-610 (Activin E antibody in late preclinical), with additional oncology bispecific programs.

Product overview

iBio is a preclinical-stage biotech company developing a pipeline of next-generation antibody therapeutics for obesity, cardiometabolic diseases, and cancer using an integrated AI Drug Discovery Platform. The platform combines three core technology components: Epitope Steering (AI-powered epitope targeting), StableHu (generative AI antibody optimization), and mammalian display-based screening. The company's lead clinical candidate IBIO-600 (anti-myostatin antibody for muscle preservation in obesity) entered Phase 1 trials in 2026. IBIO-610 (Activin E antibody for fat-selective weight loss) is in late preclinical stage with clinical trials expected in 2027. Additional programs include a myostatin x activin A bispecific antibody, bispecific T-cell engagers (EngageTx) for cancer, and masked antibody technology (ShieldTx) for improved safety. Partnered programs include Amylin receptor agonists and multiple obesity targets via AstralBio collaboration.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI Drug Discovery Platform Integrated AI-powered platform combining epitope engineering, StableHu antibody optimization, and mammalian display screening for discovering and developing precision antibodies against hard-to-drug targets. Enables progression from concept to development-ready antibody in approximately seven months. Sold/licensed to pharmaceutical partners.
  • Epitope Steering Technology Patented AI engine that directs antibody binding to precisely defined functional regions (epitopes) on target proteins. Enables creation of antibodies with complex modes of action against previously undruggable targets including GPCRs and TGF-beta family proteins. Out-licensed to pharmaceutical partners in therapeutic areas outside iBio's core focus.
  • StableHu AI Antibody Optimization Generative AI tool that predicts optimized human antibody CDR sequences and optimizes antibodies for expression, stability, and manufacturability. Trained on over 1 billion human antibody sequences. Provides focused library diversity for mammalian display optimization.
  • EngageTx CD3 T-Cell Engager Panel Next-generation CD3 antibody panel with wide range of potencies, NHP cross-reactivity, enhanced humanness, and strong tumor-killing activity with reduced cytokine release. Used for developing bispecific T-cell engagers for cancer treatment. Out-licensed to pharmaceutical partners.
  • ShieldTx Antibody Masking Technology Antibody masking technology that creates conditionally activated antibodies, keeping them inactive until reaching diseased tissue where masks are cleaved off by tissue-specific enzymes. Broadens therapeutic window and improves safety profiles. Out-licensed to pharmaceutical partners.
  • IBIO-600 Long-acting anti-myostatin monoclonal antibody designed to preserve lean mass and improve body composition in obesity patients. Targets myostatin and GDF11, engineered for infrequent dosing (2-4 times per year). Entered Phase 1 clinical trial in June 2026 for adults with overweight/obesity.
  • IBIO-610 Activin E antibody for fat-selective weight loss and weight maintenance. Demonstrated 26% reduction in fat mass with no lean mass loss in preclinical studies. Extended half-life of up to 100 days in non-human primates, supporting twice-yearly dosing. Development candidate with clinical trials expected in 2027.
  • Myostatin x Activin A Bispecific Antibody Bispecific antibody simultaneously targeting myostatin and Activin A to maximize lean mass preservation. In late discovery stage with multiple parameters being optimized. Showed stronger differentiation of progenitor cells into mature muscle cells compared to single-target antibodies.
  • IBIO-101 Second-generation anti-CD25 monoclonal antibody for immuno-oncology, designed to deplete immunosuppressive regulatory T cells while preserving interleukin-2 signaling in effector T cells. Addresses key limitations of first-generation anti-CD25 therapies.
  • TROP-2 x CD3 Bispecific Antibody Bispecific antibody developed with EngageTx platform to selectively kill TROP-2-expressing tumors while minimizing cytokine release. TROP-2 is highly expressed in breast, lung, colorectal, and pancreatic cancers. Demonstrated 36% tumor size reduction in preclinical studies.
  • MUC16 Antibody Program Antibody targeting non-shed, non-glycosylated region of MUC16 to avoid tumor immune evasion mechanisms. MUC16 is overexpressed in multiple solid tumors including over 80% of ovarian cancers. Lead molecules selectively bind engineered epitope and tumor cells.
  • CCR8 Antibody Program Anti-CCR8 antibodies with high specificity for depleting immunosuppressive tumor-associated regulatory T cells while sparing CCR4-expressing cells. Demonstrated 22% tumor size reduction in colon cancer mouse model.
  • Amylin Receptor Agonist Program Antibody-based amylin receptor agonist developed in collaboration with AstralBio for long-term weight regulation. Early DACRA-like agonist antibody showed approximately 60% reduction in acute food intake in preclinical studies.

Quantifiable outcome

  • IBIO-610 demonstrated 8.9% body weight reduction vs baseline and placebo in DIO mouse model with 26% fat mass reduction and no measurable lean mass loss
  • +4 more outcomes

Companies that use iBio

Customer profile

Segments1 record

Ideal customer profiles2 records

iBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

iBio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AstralBio, Inc.coreStrategic or Co-development Partner · 27 March 2024Discovery, Option and License Agreement entered March 27, 2024 for multi-target collaboration focused on genetically validated pathways in obesity and cardiometabolic disease. iBio granted exclusive license to its AI-powered technology to identify and engineer four targets, with options to license three obesity/cardiometabolic targets from AstralBio. Collaboration expanded in April 2025 to add a fifth target. iBio exercised options for exclusive licenses to IBIO-600 (myostatin, December 2024) and IBIO-610 (Activin E, January 2025 / April 2025), securing worldwide development and commercialization rights for both assets.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

iBio competitors and assessment

Company assessment

Broad incumbents

  • Eli Lilly: Dominant incumbent in obesity with Mounjaro/Zepbound (tirzepatide) and next-gen candidates (retatrutide). Broad incumbent defining the competitive context for iBio's muscle-preservation obesity programs and the most likely strategic acquirer/licensing partner.
  • Schrödinger: Public computational drug discovery platform serving pharma clients with physics-based and AI molecular design across small molecules and biologics. Broader incumbent in computational/AI drug discovery with established software-plus-services business model.

Emerging players

  • BioAge Labs: Clinical-stage biotech developing therapeutics for metabolic diseases including obesity, with a focus on muscle biology and aging-related pathways. Comparable emerging obesity/cardiometabolic player with overlapping target rationale (myostatin/Activin biology).
  • Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies for oncology, including T-cell engagers. Comparable to iBio's EngageTx CD3 platform and bispecific oncology pipeline (TROP-2 x CD3).
  • Structure Therapeutics: Clinical-stage company developing oral small molecules for cardiometabolic diseases including obesity and GLP-1 receptor agonists. Targets overlapping obesity patient population with a complementary (oral small molecule) modality.
  • Crinetics Pharmaceuticals: Public endocrine disease biotech with peptide platform advancing programs in acromegaly and obesity. Comparable clinical-stage obesity/cardiometabolic player, though differentiated by small molecule/peptide modality versus iBio's biologics.

Direct peers

  • Generate Biomedicines: AI-driven generative biology company developing novel protein therapeutics, including antibodies. Operates a similar AI-first antibody/protein engineering platform paradigm with comparable therapeutic ambitions across cardiometabolic and oncology indications.
  • AbCellera Biologics: Public antibody discovery platform company combining AI/machine learning with single-cell screening for therapeutic antibody discovery. Directly comparable to iBio's StableHu + mammalian display approach and serves similar biopharma partners.
  • Adagene: Clinical-stage AI-powered antibody discovery and engineering company using computational biology platforms to design antibodies with conditional activation (POWER platforms). Direct peer to iBio's ShieldTx masking and epitope steering approaches.
  • BigHat Biosciences: AI/ML-guided antibody design platform combining machine learning with wet-lab validation, including mammalian display. Direct peer to iBio's StableHu + mammalian display technology stack targeting hard-to-drug proteins.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

iBio social profiles

Digital presence

iBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iBio leadership team

Management profile

Number of profiles

Profiles7 records

iBio funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iBio M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iBio

What does iBio do?

iBio is a clinical-stage biotechnology company that discovers and develops precision antibody therapeutics for obesity and cardiometabolic diseases using an integrated AI Drug Discovery Platform. The platform combines Epitope Steering AI, StableHu generative AI antibody optimization, and mammalian display screening to engineer antibodies against hard-to-drug targets. Lead programs include IBIO-600 (anti-myostatin antibody in Phase 1) and IBIO-610 (Activin E antibody in late preclinical), with additional oncology bispecific programs.

Is iBio a public or private company?

iBio is a public company. It is classified as public and is currently operating.

When was iBio founded?

iBio was founded in 2008. It employs 51 to 100 people.

Where is iBio based?

iBio is headquartered in Newark, United States, in the North America region.

How does iBio make money?

Three revenue lines are on record. Biopharmaceutical Development & Commercialization is the primary driver. The others are strategic Licensing & Partnership Deals and financing / Capital Markets.

Who are iBio's main competitors?

Broad incumbents on record are Eli Lilly and Schrödinger. Emerging players are BioAge Labs, Compass Therapeutics, Structure Therapeutics and Crinetics Pharmaceuticals. Direct peers are Generate Biomedicines, AbCellera Biologics, Adagene and BigHat Biosciences.

Does iBio have an API?

No public API is recorded for iBio.

What industry is iBio in?

iBio's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeiBio Reports $1.1 Million Q1 Revenue and $7.6 Million Net Loss | IBIO Stock NewsiBio reported fiscal Q1 2027 revenue of $1.1 million and a net loss of $7.6 million. The company completed dosing in the single ascending dose portion of its Phase 1 trial for IBIO-600 and expects to initiate first-in-human trials of IBIO-610 in the first half of 2027.The future of tradingiBio Inc <ibio.oq> expected to post a loss of 7 cents a share - Earnings PreviewiBio Inc is expected to report a 80% revenue decline to $20,000 for the quarter ending September 30, 2026, and a loss of 7 cents per share. Analysts rate the stock a buy with a median price target of $5.50, about 644.7% above the last closing price of $0.74.Longevity.TechnologyiBio’s primate data hint at muscle-sparing obesity add-oniBio reported that its Activin E antibody IBIO-610, combined with semaglutide, caused 93% of weight loss to be fat in eight-week primate studies, versus 77% with semaglutide alone. The antibody reduced active Activin E by 97% and had a 33.2-day half-life, suggesting potential twice-yearly dosing. First-in-human trials are planned for the first half of 2027.MarketBeatiBio, Inc. (NASDAQ:IBIO) Stock Has Average Price Target of $6.00 According to AnalystsAnalysts rate iBio a Buy with an average price target of $6.00, though one has a sell rating. The stock opened at $0.78, and institutional investors increased stakes, including Headlands Technologies raising its position by 333%.Markets DailyHead to Head Comparison: Myriad Genetics (NASDAQ:MYGN) & iBio (NASDAQ:IBIO)A head-to-head comparison of iBio and Myriad Genetics evaluates institutional ownership, analyst ratings, risk, and profitability. iBio beats Myriad on 9 of 15 factors, with a consensus target price of $5.83 versus $4.02, implying a 661% upside for iBio. Myriad has higher revenue and lower valuation, but iBio is rated more favorably.Longevity.TechnologyIBIO-610 combined with semaglutide targets fat loss while protecting muscleIBIO-610 combined with semaglutide in an eight-week primate study preserved lean mass, with fat accounting for 93% of weight loss versus 77% with semaglutide alone. The drug reduced serum active Activin E by 97% and has a 33.2-day half-life, with first-in-human trials expected in 2027.The future of tradingiBio plans first-in-human trial of obesity drug candidate IBIO-610 in H1 2027iBio plans to start first-in-human trials of its obesity drug candidate IBIO-610 in the first half of 2027. Preclinical data from an obese non-human primate study, presented at EASD on Oct. 1, 2026, showed that IBIO-610 combined with semaglutide shifted weight loss toward fat, suggesting improved muscle preservation versus semaglutide alone.Ticker ReportiBio, Inc. (NASDAQ:IBIO) Stock Has Average Target Price of $5.29 According to BrokeragesiBio shares have an average analyst target price of $5.29, with a majority of ratings as buy or strong buy. The company reported a quarterly loss of $0.04 per share, beating estimates of $0.07, and analysts expect a fiscal-year loss of $0.39. Institutional investors hold 7.90% of the stock.Ticker ReportReviewing Organogenesis (NASDAQ:ORGO) & iBio (NASDAQ:IBIO)iBio and Organogenesis are compared on analyst ratings, revenue, and valuation. iBio has a higher consensus rating and potential upside of 344.18% versus Organogenesis's 207.33%, but Organogenesis has higher revenue and earnings. iBio is trading at a lower price-to-earnings ratio.Defense WorldSquarepoint Ops LLC Makes New Investment in iBio, Inc. $IBIOSquarepoint Ops LLC acquired a new stake in iBio, Inc. during Q2, buying 498,872 shares valued at about $873,000, giving it a 0.78% stake. Other hedge funds also adjusted positions, and iBio's stock opened at $1.28 after reporting a loss of $0.04 per share, beating estimates.